Statistical testing suggested a trend towards an increased frequency of PRKAG2 variants in the CHD subgroup (CHD VT: 13.04% vs. DCM VT: 3.1% and iVT: 2.7%; p-value 0.053) (Fig. S4). Here, PRKAG2 is linked to familial dilated cardiomyopathy.